NCT02539511View on ClinicalTrials.gov

Glutamatergic Modulation of Disordered Alcohol Use

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2017

Conditions
Alcohol Dependence
Interventions
DRUG

CI-581a

DRUG

CI-581b

BEHAVIORAL

Motivational Enhancement Therapy (MET)

Trial Locations (1)

10032

NYSPI, New York

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02539511 - Glutamatergic Modulation of Disordered Alcohol Use | Biotech Hunter | Biotech Hunter